Effects of different insulin sensitisers in the management of polycystic ovary syndrome: A systematic review and meta‐analysis
Authors' conclusion
Metformin should remain the first-line insulin sensitising treatment in adults with PCOS for the prevention and management of weight and metabolic features. The addition of thiazolidinediones appears to offer little benefit.
Study context
- Population
- Women with polycystic ovary syndrome (PCOS) treated with insulin sensitisers13 RCTs
- Comparison
- Metformin vs rosiglitazone vs pioglitazone
- Outcome
- Weight, BMI and testosterone: metformin vs rosiglitazone
Pooled result
As reported in the abstract
Each group vs rosiglitazoneMD (weight), kg (95% CI)
Metformin
−4.39(−7.69 to −1.08)
Each group vs rosiglitazoneMD (BMI), kg/m2 (95% CI)
Metformin
−0.95(−1.41 to −0.49)
Each group vs rosiglitazoneMD (testosterone), nmol/L (95% CI)
Metformin
−0.10(−0.18 to −0.03)
Further pooled results
Metabolic outcomes with rosiglitazone or pioglitazone added to metformin
- Adding rosiglitazone or pioglitazone to metformin did not improve metabolic outcomes
Lipid concentrations
- Rosiglitazone seemed superior to metformin in lowering lipid concentrations
Original publication
Effects of different insulin sensitisers in the management of polycystic ovary syndrome: A systematic review and meta‐analysis. Clin Endocrinol (Oxf). Published 7 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →